Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206713 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00206713: Clinical Trial Phase 3 study, sponsored by Genzyme, a Sanofi Company.
NCT00206713 is a Phase 3 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 264 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206713, a Phase 3 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
Interventions
- DRUG Placebo
- DRUG Sargramostim (Leukine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Why NCT00206713 stopped before completion
NCT00206713 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00206713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206713 about?
NCT00206713 is a clinical study titled "Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim". The purpose of this study is to evaluate whether treatment with Leukine in patients with Crohn's disease who have previously responded to Leukine can be helped again, once they have relapsed.
What is the current status of trial NCT00206713?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2004-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00206713?
The interventions under investigation include: Placebo (DRUG), Sargramostim (Leukine) (DRUG).
Who is sponsoring clinical trial NCT00206713?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206713's enrollment target sits among peer trials
264 1225th of 2000 higher than 773 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia